STREPTOZOCIN - Generic Drug Details

What are the generic drug sources for streptozocin and what is the scope of freedom to operate?

Streptozocin is the generic ingredient in one branded drug marketed by Teva Pharms Usa and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for STREPTOZOCIN

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	11
Patent Applications:	7,279
What excipients (inactive ingredients) are in STREPTOZOCIN?	STREPTOZOCIN excipients list
DailyMed Link:	STREPTOZOCIN at DailyMed

Recent Clinical Trials for STREPTOZOCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Azienda Ospedaliera Spedali Civili di Brescia	Phase 3
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Phase 3
National Cancer Institute, France	Phase 2

See all STREPTOZOCIN clinical trials

Pharmacology for STREPTOZOCIN

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for STREPTOZOCIN

Antibiotics, Antineoplastic

Anatomical Therapeutic Chemical (ATC) Classes for STREPTOZOCIN

L01AD	Nitrosoureas
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for STREPTOZOCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ZANOSAR	streptozocin	INJECTABLE;INJECTION	050577-001	May 7, 1982		RX	Yes	Yes

STREPTOZOCIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Streptozocin

Introduction to Streptozocin

Streptozocin, a chemotherapeutic agent, has been a significant player in the treatment of various medical conditions, particularly pancreatic neuroendocrine tumors (panNETs), since its FDA approval in 1982. Here, we delve into the market dynamics and financial trajectory of this drug.

Historical Context and FDA Approval

On May 7, 1982, the US Food and Drug Administration (FDA) approved streptozocin for the treatment of panNETs, marking a pivotal moment in its clinical use. This approval was the result of extensive preclinical and clinical studies that highlighted its efficacy and safety profile for this specific indication[3].

Current Market Size and Growth Projections

The global streptozocin market has shown steady growth over the years. As of 2023, the market size was valued at USD 100.2 million. It is projected to reach USD 148.7 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 6.4% from 2024 to 2031. This growth is driven by increasing incidence rates of panNETs and other conditions where streptozocin is used[4].

Pharmacokinetics and Mechanism of Action

Understanding the pharmacokinetics of streptozocin is crucial for its market dynamics. The drug has a linear and predictable pharmacokinetic profile, with a three-phase concentration/time curve. It is detectable in plasma for only 3 hours, but its metabolites remain quantifiable for 24 hours. The drug is primarily excreted through urine, with 70% of the dose detected in urine within the first 4 hours[3].

Clinical Use and Efficacy

Streptozocin is primarily used in combination with other chemotherapeutic agents such as 5-fluorouracil (5FU) and doxorubicin for the treatment of panNETs. Retrospective studies have shown varying response rates, with some reporting an overall response rate of up to 64% when used alone and higher disease control rates when used in combination therapies. For instance, the combination of STZ-5FU has shown a 39% overall response rate and an 89% disease control rate in some studies[3].

Market Drivers

Several factors drive the market growth of streptozocin:

• Increasing Incidence of PanNETs: The rising incidence of pancreatic neuroendocrine tumors globally is a significant driver. These tumors are becoming more common, leading to an increased demand for effective treatments like streptozocin[3].
• Combination Therapies: The efficacy of streptozocin when used in combination with other drugs has been well-documented, making it a preferred choice in clinical practice.
• Advancements in Diagnostic Techniques: Improved diagnostic methods have led to earlier detection of panNETs, increasing the potential patient pool for streptozocin.

Market Challenges

Despite the growth, the market faces several challenges:

• Toxicity and Side Effects: Streptozocin is known for its toxicity, which can limit its use in some patients. This has led to ongoing research for safer alternatives or combination therapies that mitigate these effects.
• Supply Chain Issues: There have been reports of streptozocin shortages in various countries, which can impact its availability and market growth[3].

Competitive Landscape

The market for streptozocin is relatively niche but competitive. Key players focus on optimizing the drug's formulation and delivery to improve its efficacy and reduce side effects. The competitive landscape is also influenced by the development of new therapies for panNETs, which could potentially replace or complement streptozocin.

Future Prospects

Looking ahead, the future of streptozocin is promising but also faces significant challenges:

• Ongoing Clinical Trials: There are ongoing clinical trials evaluating the use of streptozocin in new combinations and dosing regimens, which could expand its indications and improve outcomes.
• Emerging Therapies: The development of new drugs and therapies for panNETs could impact the market share of streptozocin. However, its established efficacy and safety profile make it likely to remain a key treatment option[3].

Financial Trajectory

The financial trajectory of streptozocin is characterized by steady growth driven by increasing demand and expanding clinical use. Here are some key financial metrics:

• Revenue Growth: The market is expected to grow from USD 100.2 million in 2023 to USD 148.7 million by 2031, at a CAGR of 6.4%[4].
• Investment in Research: Continuous investment in research and development to improve the drug's formulation and combination therapies is expected to drive further growth.

Key Takeaways

• Streptozocin has been a cornerstone in the treatment of panNETs since its FDA approval in 1982.
• The global market for streptozocin is projected to grow at a CAGR of 6.4% from 2024 to 2031.
• The drug's efficacy in combination therapies and increasing incidence of panNETs are key market drivers.
• Despite challenges such as toxicity and supply chain issues, ongoing clinical trials and research efforts are expected to sustain its market presence.

FAQs

What is the primary use of streptozocin?

Streptozocin is primarily used to treat pancreatic neuroendocrine tumors (panNETs).

What is the expected market size of streptozocin by 2031?

The global streptozocin market is expected to reach USD 148.7 million by 2031[4].

What are the common combination therapies involving streptozocin?

Streptozocin is often used in combination with 5-fluorouracil (5FU) and doxorubicin for treating panNETs[3].

What are the major challenges facing the streptozocin market?

The market faces challenges such as toxicity, side effects, and supply chain issues[3].

Are there ongoing clinical trials for streptozocin?

Yes, there are ongoing clinical trials evaluating new combinations and dosing regimens for streptozocin[3].

Cited Sources:

1. United States (US) Streptozocin Market (2024-2030) - 6Wresearch
2. Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice - MDPI
3. Streptozocin, 1982–2022: Forty Years from the FDA's Approval to ... - Karger
4. Streptozocin Market Size, Trends and Projections - Market Research Intellect